Specifically, Rh2 demonstrates versatile therapeutic potential in breast cancer by downregulating CFAP20DC-AS1, a miR-3614-3p sponge, thereby disrupting key pathways associated with proliferation and apoptosis. This evidence concerns the gene RHAG and breast carcinoma.